2024
Clinical outcomes among patients with mitral valve regurgitation undergoing Impella-supported high-risk PCI
Abu-Much A, Grines C, Chen S, Batchelor W, Zhao D, Falah B, Maini A, Redfors B, Bellumkonda L, Bharadwaj A, Moses J, Truesdell A, Zhang Y, Zhou Z, Baron S, Lansky A, Basir M, O'Neill W, Cohen D. Clinical outcomes among patients with mitral valve regurgitation undergoing Impella-supported high-risk PCI. International Journal Of Cardiology 2024, 417: 132555. PMID: 39270940, DOI: 10.1016/j.ijcard.2024.132555.Peer-Reviewed Original ResearchLower left ventricular ejection fractionMitral valve regurgitationPercutaneous coronary interventionHigh-risk PCISevere MRHigh-risk percutaneous coronary interventionMR severityPCI-related complicationsValve regurgitationIII studiesHeart failureAssociated with worse outcomesPrevalence of heart failurePresence of severe MRLower body mass indexVentricular ejection fractionStatistical significanceHigh-risk PCI patientsBody mass indexTrace MREjection fractionModerate MRClinical outcomesMild MRWorse outcomes
2023
Influence of left ventricular ejection fraction in patients undergoing contemporary pLVAD-supported high-risk PCI
Abu-Much A, Grines C, Batchelor W, Maini A, Zhang Y, Redfors B, Bellumkonda L, Bharadwaj A, Moses J, Truesdell A, Li Y, Baron S, Lansky A, Basir M, Cohen D, O'Neill W. Influence of left ventricular ejection fraction in patients undergoing contemporary pLVAD-supported high-risk PCI. American Heart Journal 2023, 269: 139-148. PMID: 38151142, DOI: 10.1016/j.ahj.2023.12.015.Peer-Reviewed Original ResearchBaseline LV ejection fractionLV ejection fractionPercutaneous coronary interventionPCI-related complicationsLV dysfunctionEjection fractionLV functionLeft main percutaneous coronary interventionHigh-risk percutaneous coronary interventionHigh-risk PCI patientsImmediate percutaneous coronary interventionMain percutaneous coronary interventionModerate LV dysfunctionSevere LV dysfunctionVentricular systolic dysfunctionVentricular ejection fractionCoronary complicationsLVEF groupMACCE rateCerebrovascular eventsPCI patientsSystolic dysfunctionCoronary interventionIII studyMyocardial infarctionImpella Utilization in High-Risk Percutaneous Coronary Intervention Mitigates the Risks of Procedural and Clinical Adverse Events Independent of Left Ventricular Ejection Fraction: The Protect III Study
Abu-Much A, Maini A, Grines C, Bharadwaj A, Moses J, Zhang Y, Redfors B, Bellumkonda L, Li Y, Truesdell A, Baron S, Lansky A, Basir M, O'Neill W. Impella Utilization in High-Risk Percutaneous Coronary Intervention Mitigates the Risks of Procedural and Clinical Adverse Events Independent of Left Ventricular Ejection Fraction: The Protect III Study. Cardiovascular Revascularization Medicine 2023, 53: s126. DOI: 10.1016/j.carrev.2023.05.290.Peer-Reviewed Original ResearchThe importance of forward flow and venous congestion in diuretic response in acute heart failure: Insights from the ESCAPE trial
Eder M, Griffin M, Moreno-Villagomez J, Bellumkonda L, Maulion C, Asher J, Wilson F, Cox Z, Ivey-Miranda J, Rao V, Butler J, Borlaug B, McCallum W, Ramos-Mastache D, Testani J. The importance of forward flow and venous congestion in diuretic response in acute heart failure: Insights from the ESCAPE trial. International Journal Of Cardiology 2023, 381: 57-61. PMID: 37023862, DOI: 10.1016/j.ijcard.2023.04.002.Peer-Reviewed Original ResearchConceptsRight atrial pressureDiuretic efficiencyRight atrial areaDiuretic responseVenous congestionHeart failureCardio-renal interactionsLoop diuretic doseAcute heart failureRenal perfusion pressureLow cardiac outputMean arterial pressureRight ventricular systolicCongestive heart failureVentricular ejection fractionNet fluid outputForward flowDiuretic doseDiuretic resistanceTTE parametersCardiac indexVentricular systolicArterial pressureAtrial pressureEjection fractionCRT-700.05 Impella Utilization in High-Risk Percutaneous Coronary Intervention Mitigates the Risks of Procedural and Clinical Adverse Events Independent of Left Ventricular Ejection Fraction: The Protect III Study
Abu-Much A, Maini A, Grines C, Bharadwaj A, Moses J, Zhang Y, Redfors B, Bellumkonda L, Li Y, Truesdell A, Baron S, Lansky A, Basir M, O'Neill W. CRT-700.05 Impella Utilization in High-Risk Percutaneous Coronary Intervention Mitigates the Risks of Procedural and Clinical Adverse Events Independent of Left Ventricular Ejection Fraction: The Protect III Study. JACC Cardiovascular Interventions 2023, 16: s107. DOI: 10.1016/j.jcin.2023.01.337.Peer-Reviewed Original Research